Imetelstat Leads to Durable Red Blood Cell Transfusion Independence

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 9, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 9, 2024 -- For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs), the competitive telomerase inhibitor imetelstat leads to durable red blood cell (RBC) transfusion independence, according to a study published online Dec. 1 in The Lancet.

Uwe Platzbecker, M.D., from University Hospital Leipzig in Germany, and colleagues compared the RBC transfusion independence rate with imetelstat versus placebo in patients with RBC transfusion-dependent LR-MDS in a double-blind trial conducted at 118 sites. Overall, 178 patients (aged 18 years and older) with ESA-relapsed, ESA-refractory, or ESA-ineligible LR-MDS were enrolled and randomly assigned to imetelstat or placebo (118 and 60, respectively), administered every four weeks as a two-hour intravenous infusion.

Patients were followed for a median of 19.5 and 17.5 months in the imetelstat and placebo groups, respectively. The researchers found that 40 and 15 percent of patients had an RBC transfusion independence of at least eight weeks in the imetelstat and placebo groups, respectively. Of the patients receiving imetelstat and placebo, 91 and 47 percent, respectively, had grade 3 to 4 treatment-emergent adverse events, with the most common events being neutropenia and thrombocytopenia for those taking imetelstat. There were no reports of treatment-related deaths.

"Taken together, IMerge phase 3 results validate the observations from the phase 2 part and show that imetelstat provides clinically significant benefit to a heavily transfusion-dependent LR-MDS patient population," the authors write.

Janssen Research & Development and Geron Corporation funded the trial before and after April 18, 2019, respectively. Geron manufactures imetelstat.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-10 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords